+69.1%
OTIS vs GSK
+91.6%
-22.5%
-33.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 10y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +1.8% | 0.0% | +1.8% | +1.8% |
| 7D | -3.0% | -3.5% | +0.6% | -1.9% |
| 30D | -6.0% | -3.4% | -2.6% | -5.0% |
| 3M | -0.9% | -8.1% | +7.3% | +1.6% |
| 6M | -17.3% | -11.1% | -6.2% | -14.4% |
| YTD | -19.6% | +0.7% | -20.3% | -20.0% |
| 1Y | -21.0% | +20.1% | -41.2% | -25.8% |
| 3Y | -12.1% | +46.1% | -58.2% | -23.8% |
| 5Y | -17.1% | +48.2% | -65.3% | -29.9% |
| All | +69.1% | +91.6% | -22.5% | +11.6% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 10y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
10y analysis · Full analysis span regression · 6 months rolling